Skip to main content

Select Drug Profiles

Perspectives
The Dream of Value-Based Care
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
Practice Management
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Kumar Mukherjee, PhD, Khalid M. Kamal, PhD
Kumar Mukherjee, PhD; Khalid M. Kamal, PhD
Stakeholder Perspective
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
F. Randy Vogenberg, RPh, PhD
by F. Randy Vogenberg, PhD, FASHP
Read More
Perspectives
Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD
Stanton R. Mehr
Stanton R. Mehr
Read More
Practice Management
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Christopher B. Atzinger, MS, PhD candidate, Jeff J. Guo, BPharm, PhD
Christopher B. Atzinger, MS, PhD candidate; Jeff J. Guo, BPharm, PhD
Stakeholder Perspective
Rheumatoid Arthritis, Biologic Drugs, and Associated Cost
Byron C. Scott, MD, MBA
by Byron C. Scott, MD, MBA
Read More
Practice Management
Top 10 Healthcare Market Trends in 2017
John Santilli, MBA, F. Randy Vogenberg, PhD, FASHP
John Santilli, MBA, and F. Randy Vogenberg, RPh, PhD
Read More
Practice Management
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD
Joseph Lee, PhD; Ryan Pelkey, MS; Julieanna Gubitosa, BS; Michael F. Henrick, MBA; Michael L. Ganz, MS, PhD
Stakeholder Perspective
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
Gary Branning, MBA
by Gary Branning, MBA
Read More
Practice Management
BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma
Chase Doyle
Read More
Leukemia, Oncology
American Society of Hematology 2016: Leukemia Highlights
Read More
Practice Management
Increased Utilization of Biosimilars in Oncology Could Save Payers Millions
Chase Doyle
Read More
Practice Management
Value Frameworks Unreliable in Assessing Novel Hematologic Therapies
Chase Doyle
Read More
Page 95 of 244
Results 941 - 950 of 2438